Furthermore, Highfill et al. showed that the efficacy of checkpoint inhibitors was limited in rhabdomyosarcoma due to the accumulation of CXCR2+ MDSCs in the TME promoting immunosuppression and tumor growth. Here, CXCR2 is linked to neoplasm.